首页> 外文期刊>Colloids and Surfaces, B. Biointerfaces >Improved oral delivery of resveratrol from N-trimethyl chitosan-g-palmitic acid surface-modified solid lipid nanoparticles
【24h】

Improved oral delivery of resveratrol from N-trimethyl chitosan-g-palmitic acid surface-modified solid lipid nanoparticles

机译:N-三甲基壳聚糖-g-棕榈酸表面改性的固体脂质纳米粒改善白藜芦醇的口服递送

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Despite the therapeutic effects of resveratrol, its clinical application is restricted by its poor oral bioavailability, low water solubility, and instability. Solid lipid nanoparticles (SLNs)-based drug delivery systems have been shown to provide excellent support for the delivery of hydrophobic drugs. The poor stability and burst release behavior in stomach acidic pH conditions of SLNs result in increased aggregation of the particles in the gastrointestinal environment, limiting the success of these particles as an oral delivery system for hydrophobic drugs. N-trimethyl chitosan (TMC) graft palmitic acid (PA) (TMC-g-PA) mucoadhesive copolymer was hypothesized to be a promising candidate for the surface modification of PA-decorated resveratrol-loaded SLNs to stabilize SLNs and circumvent all the above mentioned obstacles. TMC and TMC-g-PA copolymers were therefore synthesized and characterized by H-1-nuclear magnetic resonance (H-1 NMR) and Fourier-transformed infra-red (FT-IR) spectroscopy. Resveratrol-loaded SLNs (SLRNs) that comprised Precirol ATO 5, PA, Gelucire 50/13, Tween 80, and resveratrol as well as TMC-g-PA SLRNs were formulated and characterized in terms of physicochemical properties, stability, cytotoxicity, and in vitro and in vivo effects. The in vitro release studies of TMC-g-PA SLRNs demonstrated negligible release of resveratrol in simulated gastric and sustained release in simulated intestinal conditions and the relative bioavailability of resveratrol was furthermore found to be 3.8-fold higher from TMC-g-PA SLRNs than that from resveratrol suspension. Overall, the findings reported here indicate that TMC-g-PA SLRNs represent a potential oral drug delivery system for resveratrol. (C) 2015 Elsevier B.V. All rights reserved.
机译:尽管白藜芦醇具有治疗作用,但其临床应用受到不良的口服生物利用度,低水溶性和不稳定性的限制。基于固态脂质纳米颗粒(SLNs)的药物输送系统已显示出为疏水药物的输送提供了出色的支持。在SLNs的酸性酸性pH条件下,较差的稳定性和爆发释放行为导致在胃肠道环境中颗粒的聚集增加,从而限制了这些颗粒作为疏水性药物的口服给药系统的成功。假设N-三甲基壳聚糖(TMC)接枝棕榈酸(PA)(TMC-g-PA)粘膜粘附共聚物有望成为PA修饰的负载白藜芦醇的SLN表面改性以稳定SLN并避免上述所有问题的有前途的候选物障碍。因此,合成了TMC和TMC-g-PA共聚物,并通过H-1核磁共振(H-1 NMR)和傅立叶变换红外(FT-IR)光谱对其进行了表征。配制了包含白藜芦醇ATO 5,PA,Gelucire 50/13,Tween 80和白藜芦醇的负载白藜芦醇的SLN(SLRN),以及TMC-g-PA SLRN,并根据理化性质,稳定性,细胞毒性和体外和体内作用。 TMC-g-PA SLRNs的体外释放研究表明,白藜芦醇在模拟胃中的释放微不足道,在模拟肠道条件下持续释放,而且发现白藜芦醇的相对生物利用度比TMC-g-PA SLRNs高3.8倍白藜芦醇混悬液总体而言,此处报道的发现表明TMC-g-PA SLRNs代表了白藜芦醇的潜在口服药物递送系统。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号